These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 33230188)
1. Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5 Feng H; Liu K; Shen X; Liang J; Wang C; Qiu W; Cheng X; Zhao R Cell Death Dis; 2020 Nov; 11(11):1006. PubMed ID: 33230188 [TBL] [Abstract][Full Text] [Related]
2. Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5 Feng H; Liu K; Shen X; Liang J; Wang C; Qiu W; Cheng X; Zhao R Cell Death Dis; 2020 Oct; 11(10):916. PubMed ID: 33099574 [TBL] [Abstract][Full Text] [Related]
3. Correction: Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas. Zhang Q; Liu F Cell Death Dis; 2020 Nov; 11(11):1007. PubMed ID: 33230109 [TBL] [Abstract][Full Text] [Related]
4. ETS variant 5 promotes colorectal cancer angiogenesis by targeting platelet-derived growth factor BB. Cheng X; Jin Z; Ji X; Shen X; Feng H; Morgenlander W; Ou B; Wu H; Gao H; Ye F; Zhang Y; Peng Y; Liang J; Jiang Y; Zhang T; Qiu W; Lu X; Zhao R Int J Cancer; 2019 Jul; 145(1):179-191. PubMed ID: 30650178 [TBL] [Abstract][Full Text] [Related]
5. Response to letter to the editor from Dr Rahman Shiri: The challenging topic of suicide across occupational groups. Niedhammer I; Milner A; Witt K; Klingelschmidt J; Khireddine-Medouni I; Alexopoulos EC; Toivanen S; Chastang JF; LaMontagne AD Scand J Work Environ Health; 2018 Jan; 44(1):108-110. PubMed ID: 29218357 [TBL] [Abstract][Full Text] [Related]
11. Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer. Halama N; Herrmann C; Jaeger D; Herrmann T Anticancer Res; 2008; 28(6B):4111-5. PubMed ID: 19192669 [TBL] [Abstract][Full Text] [Related]
12. Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials. Sunakawa Y; Stintzing S; Cao S; Heinemann V; Cremolini C; Falcone A; Yang D; Zhang W; Ning Y; Stremitzer S; Matsusaka S; Yamauchi S; Parekh A; Okazaki S; Berger MD; Graver S; Mendez A; Scherer SJ; Loupakis F; Lenz HJ Ann Oncol; 2015 Dec; 26(12):2450-6. PubMed ID: 26416897 [TBL] [Abstract][Full Text] [Related]
13. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model. Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037 [TBL] [Abstract][Full Text] [Related]
15. Correction to: Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products. Selen A; Müllertz A; Kesisoglou F; Ho RJY; Cook JA; Dickinson PA; Flanagan T AAPS J; 2020 Dec; 23(1):7. PubMed ID: 33270171 [TBL] [Abstract][Full Text] [Related]
16. Specific tumor-derived CCL2 mediated by pyruvate kinase M2 in colorectal cancer cells contributes to macrophage recruitment in tumor microenvironment. Zou K; Wang Y; Hu Y; Zheng L; Xu W; Li G Tumour Biol; 2017 Mar; 39(3):1010428317695962. PubMed ID: 28347237 [TBL] [Abstract][Full Text] [Related]
17. Correction to: Laterality and sex differences in the expression of brain-derived neurotrophic factor in developing rat hippocampus. Sardar R; Zandieh Z; Namjoo Z; Soleimani M; Shirazi R; Hami J Metab Brain Dis; 2021 Oct; 36(7):2179. PubMed ID: 34146217 [TBL] [Abstract][Full Text] [Related]
18. Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer. Chiron M; Bagley RG; Pollard J; Mankoo PK; Henry C; Vincent L; Geslin C; Baltes N; Bergstrom DA Mol Cancer Ther; 2014 Jun; 13(6):1636-44. PubMed ID: 24688047 [TBL] [Abstract][Full Text] [Related]
19. [Molecular targeted therapy in colorectal cancer and its resistance]. Shitara K; Muro K Gan To Kagaku Ryoho; 2009 Apr; 36(4):557-66. PubMed ID: 19381027 [TBL] [Abstract][Full Text] [Related]
20. Oxymatrine enhanced anti-tumor effects of Bevacizumab against triple-negative breast cancer via abating Wnt/β-Catenin signaling pathway. Xie W; Zhang Y; Zhang S; Wang F; Zhang K; Huang Y; Zhou Z; Huang G; Wang J Am J Cancer Res; 2019; 9(8):1796-1814. PubMed ID: 31497360 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]